Eric Hutton Raabe, M.D., Ph.D.

Headshot of Eric Hutton Raabe
  • Associate Professor of Oncology

Languages: English, French


Brain Cancer, Medical Oncology, Pediatric Oncology more

Research Interests

Targeting stem cell factors and their downstream effectors in malignancy, specifically in brain tumors; using human neural stem cells to create genetically accurate models of aggressive brain tumors; disrupting the LIN28 pathway in brain tumors; developing novel metabolic-based therapies to disrupt MYC-driven tumors more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-8751
1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, 11th Floor
Baltimore, MD 21287
Phone: 410-614-5055
The Johns Hopkins Hospital (Main Entrance) - Google Maps


Eric Raabe, M.D., Ph.D., is an assistant professor of oncology and an instructor of pathology at Johns Hopkins School of Medicine. 

Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia.

After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a human neural stem cell system to create genetically accurate models of pediatric brain tumors.

With an interest in neuro-oncology, Dr. Raabe see patients in the pediatric oncology outpatient clinic at Johns Hopkins.

He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. more


  • Associate Professor of Oncology
  • Associate Professor of Pathology

Departments / Divisions

Centers & Institutes



  • MD; University of Cincinnati College of Medicine (2003)


  • Pediatrics; Children's Hospital of Philadelphia (2006)


  • Pediatric Oncology; Johns Hopkins University School of Medicine (2011)

Board Certifications

  • American Board of Pediatrics (Pediatric Hematology-Oncology) (2011)
  • American Board of Pediatrics (Pediatrics) (2008)

Research & Publications

Research Summary

Dr. Raabe’s research focuses on translational neuro-oncology, with the overall goal being to develop new therapeutics for poor prognosis brain tumors. Dr. Raabe’s expertise is in stem cell biology, developmental biology and pre-clinical therapeutics. He has generated one of a handful of human diffuse intrinsic pontine glioma cell lines that form xenografts with high fidelity to the primary tumor and retain the H3F3A K27M mutation. He has expertise in targeting stem cell factors in aggressive brain tumors in vivo and in vitro. Dr. Raabe has developed normal human and mouse neural stem cells for use as genetically accurate gain-of-function models for high-risk brain tumors.


Dr. Raabe currently has a research group composed of research assistants, graduate students, and post-doctoral fellows. He continues to work closely with Dr. Charles Eberhart, who is a neuro-pathologist and core collaborator.

Lab Website: Eberhart, Rodriguez and Raabe Lab

Selected Publications

View all on PubMed

Mao, XG, Hutt-Cabezas, M, Orr, BA, Weingart, M, Taylor I, Rajan K, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG*, Raabe EH*. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumor formation by enacting a pro-invasive genetic program. Oncotarget. 2013 Jul;4(7):1050-64. PMCID 3759665 * Co-corresponding author.

Kaur H, Ali SZ, Huey L, Hutt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG, Raabe EH. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016 Jul 10; 377(1):55-64. doi: 10.1016/j.canlet.2016.04.020. Epub 2016 Apr 18. PMID: 27102002

Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dancik V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees M, Shamji AF, Schreiber SL, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG*, Raabe EH*. DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets. Clin Cancer Res. 2016 Mar 24. PMID: 27012813. * Co-corresponding author.

Weingart MF, Roth J, Hutt-Cabezas M , Busse T , Kaur H, Price A, Maynard R, Rubens J, Taylor I , Mao XG, Xu J, Kuwahara Y, Allen SJ , Erdreich-Epstein A, Weissman BE , Orr BA , Eberhart CG, Biegel J, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget, 2015 Feb 20;6(5):3165-77. PMCID: PMC4413645

Raabe, E.H., Lim, K.S., Kim, JM., Meeker, A., Mao, XG., Nikkhah, G., Macizczyk, J., Kahlert, U., Jain, D., Bar, E., Cohen, KJ, Eberhart CG. "BRAF Activation Induces Transformation and then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model." Clinical Cancer Research, (2011) Jun 1;17(11):3590-9. PMCID: PMC4086658

Activities & Honors


  • Alpha Omega Alpha, University of Cincinnati College of Medicine, 2002
  • Award Winner, St. Baldrick’s Fellowship, 2008
  • Francis Schwentker Award for Excellence in Research by Pediatrics House Staff and Fellows, Johns Hopkins Hospital, 2011


  • American Association for Cancer Research, 2008
  • Children's Oncology Group, 2013
  • Sigma Xi, 1993
  • Society for Neuro-oncology, 2012

Videos & Media

Lectures and Presentations

  • Francis Schwentker Address
    Pediatrics Grand Round, Baltimore, MD (05/01/2011)
    Johns Hopkins Children's Center

Recent News Articles and Media Coverage

Common Genetic Pathway Could be Conduit to Pediatric Tumor Treatment, 11/6/13

Going After the Big Bad Tumor 6/11/13

Stem Cells May Speed Up Screening of Drugs for Rare Cancers, Johns Hopkins Medicine (August 1, 2016)

Is this you? Edit Profile
back to top button